Cambrex Corporation

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cambrex Corporation
Type Public
Traded as NYSECBM
Industry Pharmaceuticals
Founded New Jersey (1981)
Headquarters East Rutherford, NJ
Key people Steven M. Klosk, CEO, President,
Gregory P. Sargen, CFO, Executive VP
Shawn P. Cavanagh, COO, Executive VP
William M. Haskel, General Counsel and Corporate Secretary, Sr.VP
Paulo Russolo, President, Cambrex Profarmaco Milano
Revenue Increase$317.2 million USD (2013)
Employees Over 975
Website www.cambrex.com

Cambrex Corporation provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics including drug product intermediates, active pharmaceutical ingredients (API), advanced intermediates, enhanced drug delivery and other products for branded and generic pharmaceuticals..

Cambrex has R&D and cGMP manufacturing facilities in the US (Charles City, IA), Europe (Karlskoga, Sweden, Milan, Italy, Tallinn, Estonia, Wiesbaden, Germany) and Hyderabad, India. The headquarters are located in East Rutherford, NJ.

In 2007, Cambrex divested their biologics business to Lonza to focus on small molecule APIs.

History[edit]

Cambrex was founded in 1981, when the CasChem group acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco. Through multiple acquisitions during the late 1990s, Cambrex entered the bioscience and the chiral enzymatic catalyst markets. In 1998, Cambrex was listed on the NYSE. Cambrex acquired two contract biopharmaceutical manufacturing facilities, in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, Cambrex decided to focus on its core competencies and sold the biologics business to Lonza Group. In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President. To broaden their biocatalysis platform, Cambrex acquired IEP, now known as Cambrex IEP. In November 2010, Cambrex acquired a 51% stake in Zenara Pharma, providing vertical integration with Zenara's cost-effective formulation and finished dosage form capabilities.

Products[edit]

APIs and Intermediates[edit]

Cambrex manufactures a wide variety of generic and small molecule API's and intermediates and controlled substances (DEA Schedule II-IV) for the pharmaceutical and biotechnology industries.

Chiral Alcohols and Amines[edit]

In addition to the API market, Cambrex also manufactures chiral alcohols and amines for enzymatic transformations. Cambrex uses biocatalysis to create enantiometrically pure chiral alcohols and amines.

Chiral Synthesis.jpg

Fine Chemicals[edit]

Cambrex manufactures a number of fine chemicals that are used in a variety of different industries, many of which that are sold in the form of intermediates or as active pharmaceutical ingredients.

Custom Development and Manufacturing Services[edit]

Cambrex services include:

  • Custom research and development
  • cGMP manufacturing (clinical and commercial scales)
  • Process development
  • Process validation
  • Quality assurance and quality control
  • High potency/cytoxic chemistry
  • High energy chemistry
  • Screening services and custom development for chiral alcohols and amines
  • Thermal and process safety (for highly potent and high energy chemistries)
  • Toxicological assessment on unknown intermediates
  • Formulation and finished dosage form

Technologies[edit]

CF-MAOS[edit]

Continuous Flow - Microwave Assisted Organic Synthesis (CF-MAOS) was developed in 2009 by Cambrex in cooperation with C-Tech Innovation. The CF-MAOS dual technological breakthrough allows both the scale-up of microwave-assisted chemistry and the handling of heterogeneous mixtures in a continuous-flow arrangement. Cambrex’s current technology, the CaMWave KiloLAB flow reactor, is capable of manufacturing over 20 kilograms of product per day. Cambrex is currently developing larger reactors that have the potential to manufacture more than one hundred metric tons of product per year. This technology facilitates faster, cleaner, more reliable scale-up leading to improved productivity and lower manufacturing costs.

Drug Delivery[edit]

Cambrex's drug delivery platform offers products, services and technologies that allow for flexible development and manufacture of your drug delivery products, from Nicotine Replacement Therapy (NRT) development and supply to using APIs that improve taste, uptake and absorption, we have the drug delivery technology needed for the global success of your drug product.

Cambrex specializes in:

  • Cost-effective manufacturing processes, products and final dosage forms for effective nicotine replacement therapy product launches to the global market place;
  • Technology-enhanced APIs that facilitate the process for drug delivery manufacture using technologies that improve and modify formulation of APIs thereby promoting the uptake, absorption and bioavailability of molecules at optimal target sites in the body;
  • Camouflage, a proprietary technology which provides taste-masking benefits, as well as improved drug stability and controlled release.

External links[edit]